This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '19)	WHO Guidelines (DR-TB '20)	EML submitted	EML (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog	Status Yes No Rejected Ineligible for inclusion N/A
Amikacin 1000mg vial												
Amikacin 100mg vial												
Amikacin 500mg/2mL vial												
Amoxicillin/clavulanate 500mg/125mg tablet												
Bedaquiline 100mg tablet												
Clofazimine 100mg tablet/capsule												
Clofazimine 50mg tablet/capsule												

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority










This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority









This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '19)	WHO Guidelines (DR-TB '20)	EML submitted	EML (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog	Status Yes No Rejected Ineligible for inclusion N/A
Imipenem/cilastatin 500/500mg vial												
Imipenem/cilastatin/clavulanate 500/500/125 mg vial												
Isoniazid 300mg tablet/capsule												
Levofloxacin 250mg tablet/capsule												
Levofloxacin 500mg tablet/capsule												
Levofloxacin 750mg tablet/capsule												
Linezolid 400mg tablet												

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority










This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority









This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**. **Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a **Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License**.

Medicines	WHO Guidelines (DR-TB '19)	WHO Guidelines (DR-TB '20)	EML submitted	EML (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog
PAS 500mg tablet											
PAS Sodium 100gm powder											
PAS Sodium 4gm/5.52gm powder											
PAS Sodium 4gm/9.2gm powder											
Pretomanid 200mg tablet											
Protionamide 250mg tablet/capsule											
Pyrazinamide 150mg tablet scored											

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme








Status
Yes
No
Rejected

N/A



This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS**, **TB & Malaria**. **Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a **Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License**.



DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

**SRA:** Stringent Regulatory Authority









#### **Adult Drug-Sensitive TB Dashboard**

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DS-TB'17)	WHO Rapid Communication (DS-TB '21)	EML submitted	EML (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog	WHO Guidelines (LTBI '18)	WHO Guidelines (LTBI '20)	
Ethambutol 400mg tablet/capsule														
Ethambutol/Isoniazid/Pyrazinamide/ Rifampicin 275/75/400/150mg tablet/ capsule														
Ethambutol/Isoniazid/Rifampicin 275/75/150mg tablet/capsule														
Isoniazid 100mg tablet														
Isoniazid 300mg tablet/capsule														
Isoniazid/Pyrazinamide/Rifampicin 75/400/150mg tablet/capsule														
Isoniazid/Rifampicin 75/150mg tablet/capsule														
Isoniazid/Rifampicin 150/300mg tablet/capsule														
Moxifloxacin 100mg dispersible tablet														

DS-TB: Drug-Sensitive TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







Status Yes No

N/A



#### **Adult Drug-Sensitive TB Dashboard**

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DS-TB'17)	WHO Rapid Communication (DS-TB '21)	EML submitted	EML (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog	WHO Guidelines (LTBI ′18)	WHO Guidelines (LTBI ′20)
Moxifloxacin 400mg tablet/capsule													
Pyrazinamide 400mg tablet/capsule													
Pyrazinamide 500mg tablet/capsule													
Rifabutin 150mg capsule													
Rifampicin 150mg capsule													
Rifampicin 300mg capsule													
Rifapentine 150mg tablet													
Rifapentine 300mg													
Rifapentine/Isoniazid 300mg/300mg tablet													

DS-TB: Drug-Sensitive TB

EML: Essential Medicines List

EOI: Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







Status Yes No

N/A



#### Adult Latent TB Infection Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS**, **TB & Malaria**. **Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a **Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License**.

Medicines	WHO Guidelines (LTBI '18)	WHO Guidelines (LTBI '20)	EMLsubmitted	EML (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog
Isoniazid 300mg tablet/capsule											
Isoniazid/Rifampicin 75/150mg tablet/capsule											
Isoniazid/Rifampicin 150/300mg tablet/capsule											
Rifampicin 150mg capsule											
Rifampicin 300mg capsule											
Rifapentine 150mg tablet											
Rifapentine 300mg											
Rifapentine/Isoniazid 300mg/300mg tablet											

LTBI: Latent TB Infection

EML: Essential Medicines List

**EOI:** Expression of Interest **ERP:** Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







Status Yes No

N/A



#### Adult Latent TB Infection Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (LTBI '18)	WHO Guidelines (LTBI '20)	EML submitted	EML (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog	Status Yes No Ineligible for inclusion N/A
Sulfamethoxazole/Trimethoprim/ Isoniazid/Pyridoxine 800/160/300/ 25mg tablet												_

LTBI: Latent TB Infection
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority









This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '19)	WHO Guidelines (DR-TB '20)	EMLc submitted	EMLc (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog
Amikacin 100mg vial											
Amikacin 500mg/2mL vial											
Amikacin 1000mg vial											
Amoxicillin/clavulanate 500mg/125mg tablet											
Amoxicillin/clavulanic acid 125mg/31.25mg/5mL oral suspension											
Amoxicillin/clavulanic acid 250mg/62.5mg/5mL oral suspension											
Bedaquiline 20mg tablet											

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Pregualification of Medicines Programme








**Status** Yes No

N/A



This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority









This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '19)	WHO Guidelines (DR-TB '20)	EMLc submitted	EMLc (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog
Ethambutol 50mg dispersible tablet											
Ethambutol 100mg dispersible tablet											
Ethambutol 100mg tablet											
Ethionamide 125mg dispersible tablet											
Ethionamide 125mg tablet/capsule											
Isoniazid 50mg dispersible tablet											
Isoniazid 50mg tablet scored											

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Pregualification of Medicines Programme







**Status** Yes No

N/A



This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '19)	WHO Guidelines (DR-TB '20)	EMLc submitted	EMLc (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog	Status Yes No Ineligible for inclusion N/A
Isoniazid 50mg/5mL oral liquid												
Isoniazid 100mg dispersible tablet												-
Isoniazid 100mg tablet												
Isoniazid 300mg tablet/capsule												
Levofloxacin 100mg dispersible tablet												
Linezolid 20mg/mL oral suspension												
Linezolid 150mg dispersible tablet												

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

**EOI:** Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority









This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB ′19)	WHO Guidelines (DR-TB '20)	EMLc submitted	EMLc (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog	Status  Yes  No Ineligible for inclusion  N/A
Linezolid 400mg tablet												
Linezolid 600mg tablet												
Linezolid injection 2mg/mL in 300mL bag												-
Meropenem 500mg vial												
Meropenem 1000mg vial												-
Meropenem/clavulanate 1000 mg/125 mg vial												
Moxifloxacin 100mg dispersible tablet												-

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

**EOI:** Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority









This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '19)	WHO Guidelines (DR-TB '20)	EMLc submitted	EMLc (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog
Moxifloxacin 400mg tablet/capsule											
PAS 4gm granules											
PAS 500mg tablet											
PAS Sodium 4gm/5.52gm powder											
PAS Sodium 4gm/9.2gm powder											
PAS Sodium 100gm powder											
Pretomanid 200mg tablet											

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

**EOI:** Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Pregualification of Medicines Programme







**Status** Yes No

N/A



This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '19)	WHO Guidelines (DR-TB '20)	EMLc submitted	EMLc (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog
Pyrazinamide 30mg/mL oral liquid											
Pyrazinamide 150mg dispersible tablet											
Pyrazinamide 150mg tablet scored											
Streptomycin 1000mg vial											

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







Status Yes No

N/A



### **Pediatric Drug-Sensitive TB Medicines Dashboard**

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS**, **TB & Malaria**. **Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a **Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License**.

Medicines	WHO Guidelines (DS-TB '17)	WHO Rapid Communication (DS-TB '21)	EMLcsubmitted	EMLc (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog
Ethambutol 25mg/mL oral liquid											
Ethambutol 50mg dispersible tablet											
Ethambutol 100mg dispersible tablet											
Ethambutol 100mg tablet											
Isoniazid 50mg dispersible tablet											
Isoniazid 50mg tablet scored											
Isoniazid 50mg/5mL oral liquid											
Isoniazid 100mg dispersible tablet											

DS-TB: Drug-Sensitive TB

EML: Essential Medicines List

 $\hbox{\bf EOI:} \ {\sf Expression} \ {\sf of} \ {\sf Interest}$ 

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







Status
Yes
No

N/A



### **Pediatric Drug-Sensitive TB Medicines Dashboard**

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS**, **TB & Malaria**. **Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a **Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License**.

Medicines	WHO Guidelines (DS-TB '17)	WHO Rapid Communication (DS-TB '21)	EMLcsubmitted	EMLc (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog
Isoniazid 100mg tablet											
Isoniazid 300mg tablet/capsule											
Moxifloxacin 100mg dispersible tablet											
Moxifloxacin 400mg tablet/capsule											
Pyrazinamide 30mg/mL oral liquid											
Pyrazinamide 150mg dispersible tablet											
Pyrazinamide 150mg tablet scored											
Rifampicin 20mg/mL oral liquid											

**DS-TB:** Drug-Sensitive TB

EML: Essential Medicines List

**EOI:** Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







Status
Yes
No

N/A



### **Pediatric Drug-Sensitive TB Medicines Dashboard**

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DS-TB'17)	WHO Rapid Communication (DS-TB '21)	EMLcsubmitted	ЕМLс (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog	Status Yes No Ineligible for inclusion N/A
Rifampicin/Isoniazid 75/50 dispersible tablet												
Rifampicin/Isoniazid/ Pyrazinamide 75/50/150mg dispersible tablet												
Rifapentine 150mg dispersible tablet												
Rifapentine 150mg tablet												
Rifapentine 300mg												_
Rifapentine/Isoniazid 300mg/300mg tablet												

DS-TB: Drug-Sensitive TB **EML:** Essential Medicines List **EOI:** Expression of Interest **ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority









#### Pediatric Latent TB Infection Medicines Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (LTBI '18)	WHO Guidelines (LTBI ′20)	EMLcsubmitted	EMLc (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog
Isoniazid 50mg dispersible tablet											
Isoniazid 50mg tablet scored											
Isoniazid 50mg/5mL oral liquid											
Isoniazid 100mg dispersible tablet											
Isoniazid 100mg tablet											
Isoniazid 300mg tablet/capsule											
Levofloxacin 100mg dispersible tablet											
Rifampicin 20mg/mL oral liquid											

LTBI: Latent TB Infection EML: Essential Medicines List **EOI:** Expression of Interest **ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







Status Yes No

N/A



#### Pediatric Latent TB Infection Medicines Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (LTBI '18)	WHO Guidelines (LTBI '20)	EMLc submitted	EMLc (2019)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Nov 2020)	Global Fund ERP approved	GDF Catalog	Status Yes No Ineligible for inclusion N/A
Rifampicin/Isoniazid 75/50 dispersible tablet												
Rifapentine 150mg dispersible tablet												
Rifapentine 300mg												_
Sulfamethoxazole/Trimethoprim/ Isoniazid/Pyridoxine 400/80/150/ 12.5mg tablet												

LTBI: Latent TB Infection

EML: Essential Medicines List

EOI: Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority










This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



**EML:** Essential Medicines List

EOI: Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority










This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



EML: Essential Medicines List

EOI: Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority










This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



**EML:** Essential Medicines List

EOI: Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority









This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



**EML:** Essential Medicines List **EOI:** Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority





